ArticleJournal of neurology2024
Resolution of anti-LGI1-associated autoimmune encephalitis in a patient after treatment with efgartigimod.
Article in Journal of neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy of efgartigimod in the treatment of autoimmune encephalitis: a systematic review.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Pooled it
- Effectiveness and safety of efgartigimod in patients with anti-NMDAR or anti-LGI1 encephalitis and itsNeuroprotection (Chichester, England) · 2026Article
- Successful treatment with efgartigimod as rescue therapy in acute attack of MOGAD: a case report.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- Efgartigimod as an Add-on Therapy for Anti-IgLON5 Disease: A Case Report.Neurology and therapy · 2026Article
- Efgartigimod Combined with Glucocorticoids in the Treatment of Severe Generalized Myasthenia Gravis: A Single-Center, Retrospective Cohort Study.Neurology and therapy · 2026Article
- Preliminary observations on the efficacy of efgartigimod in anti-LGI1-associated autoimmune encephalitis.Therapeutic advances in neurological disorders · 2026Article
- Efficacy and safety of efgartigimod as an add-on therapy in patients with NMOSD and MOGAD at the acute attack phase.Frontiers in immunology · 2026Article
- Case Report: Sequential FcRn blockade and B-cell depletion for treatment-refractory relapsing autoimmune encephalitis: a three-patient case series.Frontiers in immunology · 2026Article
- Efgartigimod for Generalized Myasthenia Gravis and Beyond: A Narrative Review of Its Pharmacological Profile, Clinical Utility, and Expanding Applications.Biomedicines · 2025Review
- Safety and Efficacy of a Neonatal Fc Receptor Antagonist in Patients With Anti-NMDAR Encephalitis.CNS neuroscience & therapeutics · 2025Article
- Anti-kelch-like protein 11 antibody-associated encephalitis: two case reports and literature review.BMC neurology · 2025Review
- Preliminary Observations on the Efficacy of Efgartigimod Therapy in Autoimmune Nodopathy.European journal of neurology · 2025Article
- Successful treatment with efgartigimod as an add-on therapy for acute attack of anti-NMDA receptor encephalitis: a case report.BMC neurology · 2025Article
- Efgartigimod combined with steroids as a fast-acting therapy for anti-SRP immune-mediated necrotizing myopathy.Frontiers in neurology · 2025Article
- Case Report: KLHL11 encephalitis in a female patient with dual primary malignancies of breast and lung cancer: response to FcRn inhibitor therapy.Frontiers in immunology · 2025Article
- Resolution of anti-GAD-associated autoimmune encephalitis in patients treated with efgartigimod.Frontiers in neurology · 2025Article
- Successful sequential treatment with ofatumumab followed by efgartigimod for refractory autoimmune encephalitis with dual anti-NMDAR and anti-GFAP antibody positivity: first case report.Frontiers in immunology · 2025Article
- Case report: Rapid symptom relief in autoimmune encephalitis with efgartigimod: a three-patient case series.Frontiers in immunology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAnti leucine-rich, glioma inactivated 1 (LGI1) antibody-associated autoimmune encephalitis (AE) is the second most common AE, where the trafficking and recycling of the pathogenic immunoglobulin (IgG) can be controlled by the neonatal crystallizable fragment receptor (FcRn), making the latter as a candidate therapeutic target. Efgartigimod is an antagonist of FcRn, its ability to increase the degradation of IgGs and improve the health and quality of life of patients. ADAPT trail indicated its rapid efficacy and safety on myasthenia gravis. However, there is currently no case reported using efgartigimod for the treatment of anti-LGI1-associated AE. CASE DESCRIPTION: The patient presented with five episodes of generalized tonic-clonic seizures in the past 2 weeks. The patient had no abnormal signs on magnetic resonance imaging. Electroencephalogram examinations showed an increase in bilateral symmetric or asymmetric slow activity, without any clear epileptic waves. The cerebrospinal fluid (CSF) examination results indicated a slight increase in protein (47 mg/dL). The anti-LGI1 antibody titer in serum was 1:100 and that in CSF was 1:3.2. The treatment with intravenous methylprednisolone 1000 mg once a day combined with levetiracetam tablets failed to completely control the patient's seizures. Thus, 10 mg/kg efgartigimod was administered intravenously once a week for 2 weeks. After 2 weeks of treatment, serum levels of anti-LGI1 antibody and IgG decreased and the patient's epilepsy did not recur in the next 3 months.
conclusionsThis is the first case report of using efgartigimod to treat anti-LGI1-associated AE. The combination of efgartigimod and methylprednisolone resulted in favorable outcomes, indicating that this is an optional treatment plan.
Indexed as
Identifiers
38981871What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.